Free Trial
OTCMKTS:IMUC

EOM Pharmaceuticals (IMUC) Stock Price, News & Analysis

EOM Pharmaceuticals logo
$0.11 0.00 (0.00%)
As of 05/23/2025

About EOM Pharmaceuticals Stock (OTCMKTS:IMUC)

Key Stats

Today's Range
$0.11
$0.11
50-Day Range
$0.09
$0.16
52-Week Range
$0.01
$0.25
Volume
N/A
Average Volume
8,172 shs
Market Capitalization
$13.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Receive IMUC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EOM Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMUC Stock News Headlines

Q32 Bio Inc. R (DB0.BE)
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
ImmunoCellular Therapeutics, Ltd. (IMUC)
EOM Pharmaceutical Holdings Inc.
See More Headlines

IMUC Stock Analysis - Frequently Asked Questions

EOM Pharmaceuticals' stock was trading at $0.1688 at the beginning of the year. Since then, IMUC stock has decreased by 36.0% and is now trading at $0.1080.
View the best growth stocks for 2025 here
.

EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) released its quarterly earnings results on Monday, August, 13th. The company reported ($0.01) EPS for the quarter.

Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that EOM Pharmaceuticals investors own include Argos Therapeutics (ARGSQ), Nightfood (NGTF), Meta Platforms (META), LadRx (CYTR), Inovio Pharmaceuticals (INO), MannKind (MNKD) and Agenus (AGEN).

Company Calendar

Last Earnings
8/13/2018
Today
5/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:IMUC
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
122,354,000
Market Cap
$13.66 million
Optionable
Not Optionable
Beta
0.06
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:IMUC) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners